Koshinski Asset Management Inc. Purchases Shares of 1,617 Zoetis Inc. (NYSE:ZTS)

Koshinski Asset Management Inc. purchased a new stake in Zoetis Inc. (NYSE:ZTS) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 1,617 shares of the company’s stock, valued at approximately $319,000.

Other institutional investors have also recently bought and sold shares of the company. Cary Street Partners Investment Advisory LLC lifted its position in shares of Zoetis by 7.4% in the third quarter. Cary Street Partners Investment Advisory LLC now owns 93,735 shares of the company’s stock worth $16,308,000 after purchasing an additional 6,457 shares in the last quarter. Peak Financial Advisors LLC bought a new stake in shares of Zoetis in the fourth quarter worth $2,776,000. BLB&B Advisors LLC lifted its position in shares of Zoetis by 1.9% in the third quarter. BLB&B Advisors LLC now owns 60,872 shares of the company’s stock worth $10,591,000 after purchasing an additional 1,107 shares in the last quarter. Ronald Blue Trust Inc. lifted its position in shares of Zoetis by 5.4% in the third quarter. Ronald Blue Trust Inc. now owns 6,216 shares of the company’s stock worth $1,070,000 after purchasing an additional 317 shares in the last quarter. Finally, Raymond James Financial Services Advisors Inc. lifted its position in shares of Zoetis by 10.9% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 183,564 shares of the company’s stock worth $36,230,000 after purchasing an additional 17,976 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Insider Activity at Zoetis

In related news, EVP Roxanne Lagano sold 923 shares of the company’s stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $173.33, for a total value of $159,983.59. Following the transaction, the executive vice president now directly owns 15,723 shares in the company, valued at $2,725,267.59. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last three months, insiders have sold 2,209 shares of company stock worth $408,453. Corporate insiders own 0.12% of the company’s stock.

Zoetis Price Performance

NYSE:ZTS opened at $149.81 on Tuesday. Zoetis Inc. has a one year low of $148.48 and a one year high of $201.92. The company has a market cap of $68.52 billion, a P/E ratio of 29.55, a P/E/G ratio of 2.29 and a beta of 0.85. The firm’s fifty day moving average price is $179.11 and its two-hundred day moving average price is $180.74. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.36 and a quick ratio of 2.00.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, February 13th. The company reported $1.24 EPS for the quarter, missing the consensus estimate of $1.32 by ($0.08). Zoetis had a net margin of 27.43% and a return on equity of 51.25%. The company had revenue of $2.21 billion during the quarter, compared to analyst estimates of $2.19 billion. During the same quarter in the prior year, the firm earned $1.15 earnings per share. Zoetis’s revenue for the quarter was up 8.5% on a year-over-year basis. Equities analysts expect that Zoetis Inc. will post 5.8 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Friday, April 19th will be paid a $0.432 dividend. The ex-dividend date is Thursday, April 18th. This represents a $1.73 annualized dividend and a dividend yield of 1.15%. Zoetis’s dividend payout ratio (DPR) is presently 33.93%.

Analyst Ratings Changes

A number of analysts have recently commented on ZTS shares. The Goldman Sachs Group boosted their price objective on shares of Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a research report on Wednesday, January 17th. StockNews.com downgraded shares of Zoetis from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 20th. Piper Sandler boosted their target price on shares of Zoetis from $215.00 to $220.00 and gave the stock an “overweight” rating in a report on Tuesday, February 20th. Barclays boosted their target price on shares of Zoetis from $255.00 to $260.00 and gave the stock an “overweight” rating in a report on Wednesday, February 14th. Finally, Stifel Nicolaus lowered their target price on shares of Zoetis from $215.00 to $195.00 and set a “buy” rating on the stock in a report on Tuesday, April 2nd. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $224.88.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.